ECDPC data for the UK indicates MRSA was detected in 6.0 per cent of isolates in 2019 compared to 10.8 per cent in 2015. Among E. coli isolates, AMR increased for third generation cephalosporins (from 11.3 per cent in 2015 to 11.5 per cent in 2019), fluoroquinolones (15.6 per cent to 17.8 per cent), and aminoglycosides (9.9 per cent to 10.7 per cent), but fell for amoxicillin/ampicillin (65.8 per cent to 60.3 per cent) and carbapenems (0.3 per cent to zero).3 
The English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report for 2019-2020 was published in November 2020 before the effects of Covid-19 on antibiotic prescribing could be analysed. However, it highlighted pre-Covid concerns:4 
there was a 32 per cent increase in the estimated number of antibiotic resistant bloodstream infections from key bacterial species between 2015 and 2019 
one in five (21 per cent) of cases of bacteraemia involved bacteria resistant to at least one key therapeutic antibiotic 
an estimated 65,100 antibiotic-resistant severe infections occurred in 2019, equivalent to 178 new resistant infections each day. 
Changes in gonorrhoea AMR in England between 2018 and 2019 indicate increases in resistance to ciprofloxacin (up from 39.8 per cent to 42.7 per cent), penicillin (12.4 per cent to 17.9 per cent) and tetracycline (52.8 per cent to 62.9 per cent). Decreases in resistance were recorded for azithromycin (9.8 per cent to 9.3 per cent) and cefixime (2.2 per cent to 0.8 per cent).5